Ciplar

Quick links to important sections

Ciplar

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ciplar

Property Description
Active ingredient Propranolol Hydrochloride
Form Tablet, Capsule (Oral), Intravenous Solution
Pharmacological class Nonselective Beta-Adrenergic Receptor Blocker
Common use Cardiovascular support and management of tremor
Origin Synthetic Compound

What Type of Medicine is Ciplar? (Identity and Classification)

Ciplar is a prescription-only brand of medication, manufactured by Cipla Limited, with the active ingredient Propranolol Hydrochloride. It is classified as a nonselective Beta-Adrenergic Receptor Blocking Agent, commonly known as a beta-blocker. This classification signifies that the drug's fundamental function is to intervene with the body's response to stress hormones, specifically epinephrine (adrenaline) and norepinephrine, by preventing them from binding to certain nerve receptors.

The identity of Ciplar is defined by its membership in the beta-blocker class, which is clinically recognized for its wide range of therapeutic applications. Propranolol is designated as nonselective because it acts on both the beta1 receptors (primarily in the heart) and beta2 receptors (influencing areas like the lungs and blood vessels), distinguishing it from selective agents.


Ciplar's Composition and Available Forms

The pharmacological substance in Ciplar is Propranolol Hydrochloride, a synthetic chemical compound used as a single active ingredient product. The brand is specifically known for its tablet form, but the active ingredient is formulated for various routes of administration. It is most commonly supplied for oral intake as conventional tablets or as specialized oral capsules, including extended-release variants designed for sustained action. Its clinical profile identifies it as an essential cardiovascular medicine.


What is the General Purpose of Propranolol?

The general purpose of Ciplar is to reduce strain on the heart and calm cardiovascular overactivity. By blocking the effects of adrenaline, Propranolol primarily helps to slow the heart rate and decrease the force of its contractions. This fundamental action helps the heart work more efficiently and promotes control over conditions characterized by heightened systemic activity, which aids in supporting a stabilized heart rhythm and maintaining management of elevated blood pressure. A typical use scenario involves its application for prophylaxis against migraine headaches, leveraging its ability to influence vascular tone.

What side effects are possible with Ciplar?

Possible Side Effects and Safety Information

Ciplar, which contains Propranolol Hydrochloride, has an official safety profile based on regulatory documents from agencies such as the FDA and EMA. This profile details adverse reactions and critical safety constraints.

Adverse Reactions and System Involvement

Adverse reactions are classified by frequency and the body system affected (System-Organ Class or SOC). Common side effects include fatigue, dizziness, and sleep disturbances (e.g., nightmares). Other effects documented in regulatory labeling include:

System-Organ Class Examples of Documented Effects
Cardiovascular Bradycardia (slow heart rate), Hypotension, Arterial insufficiency (Raynaud type).
Nervous/Psychiatric Lightheadedness, Vivid Dreams, Mental Depression, Hallucinations.
Gastrointestinal Nausea, Vomiting, Diarrhea, Constipation.
Respiratory Bronchospasm.

Serious Adverse Reactions and Warnings

Regulatory warnings highlight serious risks. Abrupt discontinuation of Ciplar is associated with severe consequences, including the exacerbation of chest pain and the potential for Myocardial Infarction (heart attack) or Thyroid Storm. Other serious reactions include severe Bradycardia, precipitation of Cardiac Failure, severe Bronchospasm, and rare but serious skin reactions like Stevens-Johnson Syndrome (SJS).

Safety Constraints and Special Populations

Ciplar is contraindicated and must not be used in individuals with conditions such as bronchial asthma, cardiogenic shock, decompensated heart failure, or greater than first-degree heart block.

Specific cautions apply to certain groups:

  • Diabetic Patients: The medication may mask key warning signs of low blood sugar (hypoglycemia), such as a rapid heartbeat.
  • Patients with Hepatic Impairment: Caution is required, as liver function may deteriorate, with the potential for hepatic encephalopathy in those with decompensated cirrhosis.
  • Pediatric Patients: There is a documented risk of hypoglycemia, especially during periods of fasting or illness.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Ciplar

The official regulatory documents for Propranolol Hydrochloride (Ciplar) define overdose primarily through its severe impact on the cardiovascular and central nervous systems, which requires immediate attention.


Documented Overdose Manifestations

Official labeling describes that an overdose may present with profound symptoms across several systems:

  • Cardiovascular: Severe bradycardia (slow heart rate), hypotension (low blood pressure), heart block, and the risk of life-threatening cardiogenic shock or cardiovascular collapse.
  • CNS: Drowsiness, confusion, coma, and seizures (convulsions) are documented central nervous system effects.
  • Other: Bronchospasm and hypoglycemia (low blood sugar) are specifically listed as documented complications, with hypoglycemia being a noted risk in children.

Regulator-Mandated Emergency Actions

Immediate medical assistance is required for any suspected overdose. Regulator-derived statements instruct patients to seek urgent medical assistance immediately if an overdose has been taken or if extreme cardiac symptoms occur, such as a severe fall in heart rate or blood pressure.

Management focuses on symptomatic and supportive care, as no specific antidote is known. Officially documented supportive measures include continuous ECG and vital sign monitoring, and the use of agents like intravenous Glucagon or Atropine to manage severe cardiovascular depression in a supervised setting. Monitoring may be extended for cases involving sustained-release preparations.

Therapeutic Uses of Ciplar

What Ciplar Treats: Main Uses and Benefits

Ciplar (Propranolol) is commonly used across conditions characterized by periods of heightened symptoms and is considered relevant in contexts involving heightened systemic burden. These applications may assist with management across several major symptomatic domains.

The medication plays a role in managing conditions such as high blood pressure (hypertension), recurrent chest pain (angina pectoris), irregular heart rhythms, and the involuntary shaking of essential tremor. It is applied in situations involving recurrent or episodic manifestations, such as migraine headaches, and for supportive relief during episodes of systemic overactivity, such as those related to an overactive thyroid. This range of application provides support that helps ease the overall symptom load.

In clinical scenarios, Ciplar is often used when symptoms intensify and supportive relief is needed. By calming the symptoms related to heightened physiological activity—like a racing heart or trembling—it contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.


Quick Fact: Relief for Symptoms Related to Heightened Physiological Activity

Regulatory References

  1. NIH MedlinePlus overview on Propranolol

Eligibility and Restrictions for Use

Ciplar (propranolol hydrochloride) is governed by strict regulatory eligibility rules defining the patient population that must not use the medicine and those who require careful monitoring.

Populations for Whom Use is Contraindicated

Official government labels specify that Ciplar must not be used in patients with:

  • Cardiogenic Shock or Uncontrolled Congestive Heart Failure (except when failure is secondary to a treatable arrhythmia).
  • Sinus Bradycardia or Greater than first-degree heart block (second or third degree block) without a functional pacemaker.
  • Bronchial Asthma or a history of Bronchospasm.
  • Hypersensitivity to propranolol hydrochloride or any component of the formulation.
  • Hypoglycemia or conditions predisposing to it (e.g., following prolonged fasting).

Eligibility-Related Restrictions

Population/Condition Official Regulatory Status
**Pregnancy** Conditional Use. Should be used only if the potential benefit justifies the potential risk to the fetus (e.g., FDA Category C).
**Lactation** (Breastfeeding) Conditional Use. Propranolol is excreted in human milk; caution is advised, and the infant must be monitored.
**Impaired Hepatic/Renal Function** Restricted Use. Requires caution and potential dose adjustments due to altered drug clearance.
**Chronic Obstructive Pulmonary Disease (COPD)** Restricted Use. Beta-blockers should generally be avoided; administer with caution.
**Pediatric Population** Conditional Use. Efficacy and safety are not established for all indications in all pediatric groups; use for infantile hemangioma is established only for specific ages.

These official eligibility statements ensure the medicine is reserved for the patient population where the risks are manageable and well-understood relative to the treatment needs, while strictly excluding individuals with specific life-threatening cardiovascular or respiratory instabilities.

What should I know about interactions with other medicines?

Ciplar (propranolol) is susceptible to pharmacokinetic drug interactions because its metabolism involves multiple pathways in the Cytochrome P-450 (CYP) enzyme system, specifically CYP2D6, CYP1A2, and CYP2C19. Changes in the activity of these enzymes by co-administered medicines can significantly alter the concentration of propranolol in the body.

Interactions that Increase Propranolol Concentration

Co-administration with inhibitors of CYP2D6 (e.g., cimetidine, fluoxetine, quinidine) or inhibitors of CYP1A2 and CYP2C19 (e.g., ciprofloxacin, fluconazole, fluvoxamine) generally increases the exposure of propranolol. Antiarrhythmics like quinidine and propafenone, and calcium channel blockers such as nicardipine and nisoldipine, have also been officially documented to increase propranolol concentrations.

Interactions that Decrease Propranolol Concentration

Drugs that induce hepatic metabolism, such as rifampin, can decrease propranolol plasma levels, potentially resulting in a loss of its therapeutic effect. The use of certain antacids (e.g., aluminum hydroxide gel) may also lead to reduced absorption and lower peak propranolol concentrations. Additionally, cigarette smoking is noted as an inducer of hepatic metabolism that significantly increases propranolol clearance.

Propranolol's Effect on Other Medicines

Propranolol may also inhibit the metabolism of certain co-administered drugs. For instance, it has been shown to increase the blood levels of lidocaine, theophylline, and triptans (e.g., rizatriptan, zolmitriptan) and to affect the concentration of certain oral anticoagulants like warfarin. The co-administration of propranolol with other heart rate-lowering medicines, such as digoxin or other antiarrhythmics, may increase the risk of an overly slow heart rate.

Mechanism of Action

Ciplar, containing propranolol, functions as a non-selective beta-adrenergic receptor antagonist.

Its primary biological targets are the beta1 and beta2 adrenoceptors, where it engages in competitive inhibition against endogenous catecholamines, specifically epinephrine and norepinephrine.

Cellular and Systemic Effects

  • beta1 Receptor Blockade: Predominantly located on cardiac myocytes and in the conduction system, this antagonism prevents the Gs-protein-coupled pathway activation which normally increases intracellular cyclic AMP (cAMP). The resulting intracellular consequence is a reduction in the phosphorylation of L-type calcium channels, leading to a decrease in calcium influx. This mechanism results in a negative chronotropic effect (decreased heart rate) and a negative inotropic effect (decreased myocardial contractility).

  • beta2 Receptor Blockade: Located in bronchial and vascular smooth muscle, this antagonism prevents receptor-mediated relaxation. This beta2 blockade can consequently modulate local smooth muscle tone.

  • System-Level Consequences: The net system-level physiological modulation is a diminution of sympathetic-mediated stimulation, resulting in a reduction in cardiac output and suppression of renin release from the juxtaglomerular apparatus, contributing to modified systemic vascular dynamics and centralized sympathetic outflow.

Dosage and Administration Information

Ciplar (Propranolol) is administered either orally or intravenously (IV), based on the clinical setting. The oral forms include Immediate-Release (IR) tablets and Sustained-Release (SR) capsules. The IR forms typically require administration multiple times a day (e.g., two to four times daily), while the SR capsules are intended for a once daily (QD) regimen.

The start of therapy involves a dose titration process, where the initial low dose (e.g., 40 mg twice daily for hypertension) is gradually increased over set intervals, often weekly, until the specific maintenance range is achieved. Maximum labeled daily doses vary but can extend up to 640 mg depending on the indication. Intravenous administration is reserved for acute, supervised scenarios and involves injecting a small dose slowly, at a rate not exceeding 1 mg per minute.

Administration timing may be required to be consistent. For example, certain SR formulations should be taken once daily at bedtime and consistently with or without food. Pediatric liquid forms, specifically approved for certain uses, must be given during or right after a feeding and require periodic dose readjustment based on body weight.

Finally, the official usage protocol mandates that therapy must not be stopped abruptly. Instead, the daily amount must be gradually reduced over a period of 7 to 14 days to complete the course of use.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Ciplar, which contains the active substance propranolol, is a non-selective beta-adrenergic receptor blocking agent. Extensive clinical research has established its role in managing several cardiovascular and neurological conditions. Recent evidence and meta-analyses continue to support its use across various indications, primarily by modulating the body's response to nerve impulses, thereby slowing the heart rate and relaxing blood vessels.


Key Areas of Research

Research has concentrated on several established and emerging uses of propranolol:

  • Cardiovascular Health: Studies consistently show propranolol's association with a reduced risk of death and non-fatal reinfarction following a myocardial infarction (heart attack). It is also a foundational treatment in managing high blood pressure (hypertension) and angina pectoris (chest pain).
  • Migraine Prevention: Clinical trials have explored its effectiveness as a prophylactic (preventative) treatment for migraine headaches, focusing on reducing the frequency and severity of episodes.
  • Essential Tremor: Propranolol is one of the most studied and utilized pharmacological treatments for essential tremor, with research focusing on its ability to reduce tremor amplitude.

Summary of Clinical Findings

Condition Research Focus Key Findings
Post-MI Survival Randomized trials in post-myocardial infarction patients. Associated with a reduction in cardiovascular mortality and risk of recurrent heart events.
Migraine Prophylaxis Studies assessing frequency and severity of headache attacks. May contribute to reduced frequency of migraine attacks in some patients.
Anxiety/Tremor Studies on the physical symptoms of situational anxiety and essential tremor. Research suggests its use can help manage the physical manifestations (e.g., palpitations, trembling) associated with these conditions.

It is important to note that the specific mechanism of action for certain neurological uses, such as migraine and tremor, is not yet fully defined in research, but clinical findings support its benefit in those areas. Continuous monitoring and individualized dosing remain critical, as patient response to propranolol can vary significantly.

Frequently Asked Questions (FAQ)

Common questions about Ciplar (FAQ)


Q: How quickly does Ciplar start to have an effect?

A: Official product information indicates that the immediate-release (IR) form generally begins to show an initial effect on the heart rate within one to two hours of taking a dose. The maximum concentration of the drug in the bloodstream for the IR form is typically reached within this same 1- to 2-hour period.

Q: Does Ciplar interact with common pain relievers like ibuprofen?

A: Regulatory-based information suggests that combining propranolol with nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a potential to lessen the blood pressure-lowering effect of propranolol, particularly when the pain reliever is used frequently.

Q: Does Ciplar have a 'peak' time in the body?

A: Yes, the official pharmacokinetic data describes a 'peak time' in the body. For the standard immediate-release (IR) form, the highest concentration in the blood is typically reached one to two hours after a dose. Extended-release (ER) capsules are designed for slower absorption and generally reach their peak around six hours.

Q: Are there any common interactions with supplements or herbal remedies?

A: Official labeling describes the importance of a healthcare provider being aware of all co-administered products, including herbal and supplement remedies. This is necessary because these products have the potential to alter the effects or blood concentration of Ciplar.

Q: How long after starting Ciplar should I expect to see the full effect?

A: For long-term conditions such as managing high blood pressure, the time needed to see the full therapeutic response can vary significantly among individuals. Regulatory information suggests it may take from a few days up to several weeks of consistent use to achieve the maximal desired effect.

Q: Can Ciplar interfere with driving or operating machinery?

A: Common side effects listed in official patient warnings include dizziness, lightheadedness, and fatigue. Official patient warnings state that due to these effects, use of hazardous machinery or driving should be approached with caution until the drug's effect is known.

Q: What are the standard frequency of taking Ciplar?

A: The way Ciplar is taken depends on the specific form prescribed. Immediate-release tablets are typically administered multiple times daily, often two to four times. Extended-release capsules are specifically formulated for once-daily dosing.

Q: What is the difference between Ciplar and other 'ol' ending drugs?

A: Ciplar's active ingredient, propranolol, is officially defined as a non-selective beta-adrenergic receptor blocker. This means it acts on both beta1 receptors (primarily in the heart) and beta2 receptors (in the lungs and blood vessels). Other medicines in this class may be selective for only one receptor type.

Q: Can Ciplar be taken on an empty stomach?

A: Official administration instructions emphasize the importance of taking the medicine consistently, either always with food or always without food. This consistency helps to keep the drug levels stable in the body.

Q: Is it common to have vivid dreams when taking Ciplar?

A: Vivid Dreams are listed as a documented adverse event within the central nervous system category. For the immediate-release form, official regulatory data notes that the frequency of experiencing vivid dreams appears to be related to the dosage amount.

Q: Can drinking alcohol while taking Ciplar be dangerous?

A: Regulatory-based interaction information suggests that taking Ciplar with alcohol is associated with an increased potential for central nervous system effects, such as drowsiness and dizziness. It may also have additive effects in lowering blood pressure.

Q: Are there any foods or drinks to avoid when using Ciplar?

A: The official interaction section notes that co-administration with certain antacids (like aluminum hydroxide gel) can reduce the absorption of the medicine. Aside from this, consistency in administration (with or without food) is the key instruction.

Q: Can Ciplar affect blood sugar levels?

A: Yes, official warnings confirm that propranolol may mask the symptoms of low blood sugar (hypoglycemia), such as a rapid heartbeat or tremor. This is a specific caution for patients with diabetes.

Q: Does Ciplar work for headaches other than migraines?

A: Propranolol is officially indicated for the prophylaxis (prevention) of common migraine headaches. Its effectiveness for treating other types of headaches is not listed among its official indications.

Q: Can Ciplar cause hair loss?

A: The official safety profile lists alopecia (hair loss) among the documented, though generally rare, adverse events reported in the skin and mucous membranes category.

Q: How does Ciplar affect heart rate?

A: Propranolol's primary mechanism of action is to block the effects of adrenaline on the heart. This results in a negative chronotropic effect, which is the physiological action that causes the decrease in heart rate.

Q: Can Ciplar affect sleep patterns?

A: The adverse event section of the official documents lists sleep disturbances and insomnia as documented side effects. This indicates a potential effect on an individual's normal sleep pattern.

Q: Is it normal to feel cold hands or feet while on Ciplar?

A: Official documents list arterial insufficiency (Raynaud type) as a documented cardiovascular side effect. This condition, which can involve reduced blood flow to the extremities, often results in feelings of coldness in the hands and feet.

Q: Does Ciplar have a risk of withdrawal symptoms?

A: The official label contains a boxed warning about the risks associated with abrupt discontinuation. This action can lead to severe adverse consequences, including the exacerbation of chest pain and the potential for a heart attack.

Q: Can Ciplar be crushed or split if the tablet is too big?

A: Extended-release (ER) capsules are explicitly designed not to be opened, crushed, or chewed. Regulatory instructions state that altering these forms can compromise the special mechanism that allows the medicine to be released slowly over time.

Q: Has Ciplar been studied in children or adolescents?

A: Regulatory sections on Pediatric Use confirm that the efficacy and safety of propranolol are not established for all indications in all pediatric groups. However, the medicine is used for some specific conditions in this population, such as infantile hemangioma.

Q: Is Ciplar a controlled substance?

A: Propranolol, the active ingredient, is not listed as a controlled substance under the schedules of the U.S. Drug Enforcement Administration (DEA).

Q: Does Ciplar affect kidney function?

A: Regulatory sections note the requirement for caution and potential dose adjustment in patients with known impaired renal function due to a potential change in drug clearance.

Q: Can Ciplar be taken with antacids?

A: The official interaction section notes that co-administration with certain antacids (such as aluminum hydroxide gel) can reduce the absorption and subsequently lower the blood concentration of propranolol.

Q: What types of allergic reactions are associated with Ciplar?

A: The label lists hypersensitivity as a contraindication. Rare but severe allergic reactions such as Stevens-Johnson Syndrome (SJS) are documented in the serious adverse reactions section.

Q: Is Ciplar used to prevent future health issues?

A: Yes, the drug is officially indicated for prophylactic use (preventative use) in certain conditions. This includes the prevention of migraine headaches and the reduction of cardiovascular risk following a myocardial infarction (heart attack).

Q: Does Ciplar interact with smoking or nicotine products?

A: Official documentation notes that cigarette smoking significantly increases the metabolic clearance of propranolol, which can potentially lead to a reduction in its concentration in the blood.

Q: How is Ciplar typically stopped if a person needs to discontinue it?

A: Official instructions mandate that therapy must not be stopped abruptly. Instead, the daily amount must be gradually reduced over a period, often 7 to 14 days, as determined by a healthcare professional.

Q: Is Ciplar known to cause dry mouth?

A: Dry mouth has been reported as an adverse event associated with the use of propranolol, according to regulatory data. However, it is not consistently listed as a common or frequent side effect in all primary regulatory documents.

How should Ciplar be stored and disposed of?

Official Storage and Disposal Instructions

Propranolol hydrochloride, the active ingredient in Ciplar, must be stored according to specific environmental and safety constraints defined in regulatory labeling.

Storage & Handling Requirements Official Regulatory Statement
Temperature Range Store at controlled room temperature (20^circ to 25^circ C or 68^circ to 77^circ F).
Protection Conditions Must be stored in a tightly closed, light-resistant container and protected from excessive moisture and heat.
Child Safety Keep this medication out of the sight and reach of children.
General Disposal Rule Do not flush unused medicine down the toilet or pour it down a drain unless the product label explicitly instructs otherwise.
Household Disposal If a take-back program is unavailable, mix the unused medicine with an undesirable substance (like coffee grounds or kitty litter), seal the mixture in a container, and discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ciplar found in:

A-Z Index: